AI Verdict
BSX has stronger fundamentals based on our AI analysis.
ABBV vs BSX Fundamental Comparison
| Metric | ABBV | BSX |
|---|---|---|
| Revenue | $61.2B | $20.1B |
| Net Income | $4.2B | $2.9B |
| Net Margin | 6.9% | 14.4% |
| ROE | N/A | 12.0% |
| ROA | 3.2% | 6.6% |
| Current Ratio | 0.67x | 1.62x |
| Debt/Equity | N/A | 0.46x |
| EPS | $2.36 | $1.94 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABBV vs BSX: Frequently Asked Questions
Is ABBV or BSX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), BSX has stronger fundamentals. ABBV is rated HOLD (70% confidence) while BSX is rated BUY (80% confidence). This is not investment advice.
How does ABBV compare to BSX fundamentally?
AbbVie Inc. has ROE of N/A vs BOSTON SCIENTIFIC CORP's 12.0%. Net margins are 6.9% vs 14.4% respectively.
Which stock pays higher dividends, ABBV or BSX?
ABBV has a dividend yield of N/A or no dividend while BSX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABBV or BSX for long term?
For long-term investing, consider that ABBV has HOLD rating with 70% confidence, while BSX has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABBV vs BSX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABBV vs BSX, the AI consensus favors BSX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.